Previous 10 | Next 10 |
Following a second independent Data Safety Monitoring Board (DSMB) safety review, RedHill Biopharma ([[RDHL]] +0.1%) has received a second unanimous recommendation to continue its global Phase 2/3 study testing Opaganib in hospitalized patients with severe COVID-19 pneumonia.Th...
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety d...
RedHill Biopharma ([[RDHL]] +3.9%) has announced promising preliminary results from a preclinical study within which opaganib, an orally administered sphingosine kinase 2 selective inhibitor, demonstrated a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome ((A...
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model TEL AVIV, Israel and RALEIGH, N.C. , Dec. 15, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmace...
The specialty biopharmaceutical company, RedHill Biopharma (RDHL) announces, the company will become a part of the NASDAQ Biotechnology Index with effect from December 21, 2020.Ahead of the demand from the funds tracking the index, the stock is trading +7.7% higher in the pre-market...
RedHill Biopharma Added to NASDAQ Biotechnology Index TEL AVIV, Israel and RALEIGH, N.C. , Dec. 14, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the company wa...
RedHill has a stable line of approved, marketed and pipeline products. Its cash balance is a little low. The company looks interesting for a long-term, low risk appetite investor. For further details see: RedHill: A Slow And Steady Climb Towards Biopharma Success
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans TEL AVIV, Israel and RALEIGH, N.C. , Dec. 7, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Compa...
RedHill Biopharma ([[RDHL]] +3.6%) partners with two leading, U.S.-based manufacturers for large-scale manufacturing of Opaganib. These collaborations further advance ongoing preparations to support potential emergency use applications.This new collaborations follow recently announced collabo...
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new ...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...